Get the Stockscreener App
208.84
2.86%
-6.14
Pre-market:
208.50
-0.34
-0.16%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $208.84, with a volume of 5.08M.
It is down -2.86% in the last 24 hours and down -10.85% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$214.98
Open:
$213.99
24h Volume:
5.08M
Relative Volume:
0.72
Market Cap:
$369.39B
Revenue:
$61.16B
Net Income/Loss:
$4.19B
P/E Ratio:
88.44
EPS:
2.3614
Net Cash Flow:
$17.82B
1W Performance:
-1.08%
1M Performance:
-10.85%
6M Performance:
-11.72%
1Y Performance:
+1.78%
1-Day Range:
$207.71
$214.56
1-Week Range:
$207.71
$220.45
52-Week Range:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
208.84 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
935.58 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
243.04 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
203.49 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.87 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
The Best Dividend ETF to Buy in April 2026 If You Want Passive Income - The Motley Fool
AbbVie Inc. $ABBV Shares Purchased by Kelleher Financial Advisors - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by JB Capital LLC - MarketBeat
Savvy Advisors Inc. Buys 6,646 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie Inc. $ABBV is Advocate Group LLC's 4th Largest Position - MarketBeat
AbbVie's Financial Outlook Revised Amid Pipeline Progress and One-Time Charge - AD HOC NEWS
AbbVie Updates 2026 Adjusted EPS Guidance to $13.96–$14.16 Including Q1 Acquired IPR&D and Milestones Expense 1 - Minichart
AbbVie Inc. $ABBV Shares Bought by SteelPeak Wealth LLC - MarketBeat
Thurston Springer Miller Herd & Titak Inc. Acquires 6,946 Shares of AbbVie Inc. $ABBV - MarketBeat
C2P Capital Advisory Group Trims AbbVie Stake - National Today
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Sells 8,610 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) latest stock news and headlines - Yahoo Finance Australia
AbbVie reports $744 million IPR&D expense for Q1, updates 2026 earnings guidance - Investing.com
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026News and Statistics - IndexBox
Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034 – DelveInsight | Visiox Pharma, TearClear, VivaVision Biotech, Abbvie, Ocuphire Pharma, Qlaris Bio, Nicox Ophthalmics, Sun Pharma - barchart.com
AbbVie Posts Record $61B Revenue as Skyrizi and Rinvoq Surge Past Peak Humira Sales - tikr.com
Potential US Drug Tariffs Test AbbVie Margins And Growth Narrative - Yahoo Finance
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know - Yahoo Finance
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
AbbVie Inc Stock (ABBV) Moved Down by 3.20% on Apr 2: A Full Analysis - tradingkey.com
AbbVie stock price forecast: Downside risk builds as ABBV drops 3.07% to $208 - Traders Union
AbbVie Inc. $ABBV Shares Sold by Trust Co. of Vermont - MarketBeat
Assessing AbbVie (ABBV) Valuation After New Dermatology Data And FDA Label Update - Yahoo Finance
Compagnie Lombard Odier SCmA Raises Holdings in AbbVie Inc. $ABBV - MarketBeat
Banque Pictet & Cie SA Has $88.87 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
What You Need to Know Ahead of AbbVie’s Earnings Release - Barchart
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Thrivent Moderate Allocation Fund's AbbVie Inc(ABBV) Holding History - gurufocus.com
AbbVie Inc. $ABBV Stock Holdings Trimmed by Vaughan Nelson Investment Management L.P. - MarketBeat
Nisa Investment Advisors LLC Has $156 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Moody Lynn & Lieberson LLC Has $43.98 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Meyer Handelman Co. Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Sarcopenia Treatments Market Is Going to Boom | AbbVie • Amgen • Pfizer • Novartis - openPR.com
AbbVie Inc. $ABBV Shares Bought by Capital Advisors Inc. OK - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 2%Time to Buy? - MarketBeat
AbbVie Inc. stock rises Tuesday, still underperforms market - MarketWatch
Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit - Bloomberg Law News
ABBV Stock Quote Price and Forecast - CNN
Bernstein Maintains AbbVie(ABBV.US) With Hold Rating, Maintains Target Price $225 - 富途牛牛
AbbVie Inc Stock (ABBV) Moved Up by 3.26% on Mar 31: Drivers Behind the Movement - TradingKey
/C O R R E C T I O N -- AbbVie/ - Investing News Network
Will AbbVie's Oncology Drugs Aid Top Line in 2026? - The Globe and Mail
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting - Investing News Network
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® - AbbVie News Center
AbbVie to Host First-Quarter 2026 Earnings Call - National Today
AbbVie to Host First-Quarter 2026 Earnings Conference Call - Moomoo
Range Financial Group LLC Has $1.08 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
J. Safra Sarasin Holding AG Reduces AbbVie Stake - National Today
J. Safra Sarasin Holding AG Sells 36,172 Shares of AbbVie Inc. $ABBV - MarketBeat
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.37%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):